Napyradiomycin B4
Napyradiomycin B4 is a Napyradiomycin derivative, which inhibits the RANKL-induced MEK-ERK signaling pathway. Napyradiomycin B4 attenuates osteoclastogenesis and prevents alveolar bone destruction in experimental periodontitis[1].
Product Specifications
UNSPSC
12352005
Target
ERK; MEK
Type
Natural Products
Related Pathways
MAPK/ERK Pathway; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Others
Assay Protocol
https://www.medchemexpress.com/napyradiomycin-b4.html
Solubility
10 mM in DMSO
Smiles
Cl[C@](C(C1=C(O)C=C(O)C=C1C2=O)=O)(C[C@H](C(C)(O3)C)Cl)[C@]23C[C@H]4C(C)([C@H](CC[C@@]4(O)C)Cl)C
Molecular Formula
C25H31Cl3O6
Molecular Weight
533.87
References & Citations
[1]Kim JA, et al., Napyradiomycin B4 Suppresses RANKL-Induced Osteoclastogenesis and Prevents Alveolar Bone Destruction in Experimental Periodontitis. ACS Pharmacol Transl Sci. 2024 Apr 3;7 (4) :1023-1031.
Shipping Conditions
Room temperature
Scientific Category
Natural Products
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TP314435M 100 µg
Cyclophilin E (PPIE) (NM_006112) Human Recombinant Protein
Sign In for Pricing
View Details 
